Quick Answer
HALOZYME THERAPEUTICS, INC. reported Net Income Loss of $316.89 million for the year ending 2025.
- HALOZYME THERAPEUTICS, INC. showed a decrease of -28.6% in Net Income Loss from 2024 to 2025.
- This data is from HALOZYME THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$26.55 million | Q2 2014: -$16.27 million | Q3 2014: -$20.28 million | Q4 2014: -$5.27 million | Q1 2015: -$19.82 million | Q2 2015: -$26.88 million | Q3 2015: -$28.95 million | Q4 2015: -$27.39 million | Q1 2016: -$19.82 million | Q2 2016: -$26.88 million | Q3 2016: -$28.95 million | Q4 2016: -$27.39 million | Q1 2017: -$32.90 million | Q2 2017: -$30.76 million | Q3 2017: $2.75 million | Q4 2017: $123.88 million | Q1 2018: -$27.46 million | Q2 2018: -$22.89 million | Q3 2018: -$27.85 million | Q4 2018: -$2.13 million | Q1 2019: $1.80 million | Q2 2019: -$14.62 million | Q3 2019: -$25.02 million | Q4 2019: -$34.40 million | Q1 2020: -$6.10 million | Q2 2020: $25.82 million | Q3 2020: $36.21 million | Q4 2020: $73.16 million | Q1 2021: $27.90 million | Q2 2021: $91.46 million | Q3 2021: $216.59 million | Q1 2022: $60.11 million | Q2 2022: $22.69 million | Q3 2022: $61.63 million | Q1 2023: $39.62 million | Q2 2023: $74.75 million | Q3 2023: $81.84 million | Q1 2024: $76.82 million | Q2 2024: $93.25 million | Q3 2024: $137.01 million | Q1 2025: $118.10 million | Q2 2025: $165.16 million | Q3 2025: $175.23 million.
- Over the full 17 years of available data (2009 to 2025), HALOZYME THERAPEUTICS, INC.'s Net Income Loss has grown by 643.0%.
- Historical annual values: Fiscal year 2025: $316.89 million | Fiscal year 2024: $444.09 million | Fiscal year 2023: $281.59 million | Fiscal year 2022: $202.13 million | Fiscal year 2021: $402.71 million | Fiscal year 2020: $129.09 million | Fiscal year 2019: -$72.24 million | Fiscal year 2018: -$80.33 million | Fiscal year 2017: $62.97 million | Fiscal year 2016: -$103.02 million | Fiscal year 2015: -$32.23 million | Fiscal year 2014: -$68.38 million | Fiscal year 2013: -$83.48 million | Fiscal year 2012: -$53.55 million | Fiscal year 2011: -$19.77 million | Fiscal year 2010: -$53.24 million | Fiscal year 2009: -$58.36 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: